Dinutuximab‐containing immunotherapy vs usual care
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
- Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes onlyHR 0.5 [0.31, 0.8]1 study · 226 participantsModerate